Abstract The key transcription factor that regulates the cellular responses to hypoxia is hypoxia inducible factor-1 (HIF-1). The signaling mechanisms that regulate the hypoxic activation of HIF-1 are not fully understood. Our objective here was to test whether AMP-activated kinase (AMPK) was an upstream regulator of HIF-1. Our results show that AMPK is not required for the hypoxic activation of HIF-1. Interestingly, the AMPK inhibitor, Compound C, inhibits the hypoxic activation of HIF-1 independent of AMPK. Furthermore, we demonstrate that Compound C functions as a repressor of HIF-1 by inhibiting respiration and suppressing mitochondrial generated ROS.
Introduction
Hypoxia is the reduction in normal oxygen tension and occurs during acute and chronic vascular disease, pulmonary disease and cancer. Hypoxia inducible factor 1 (HIF-1) is the master transcription factor that regulates the cellular responses to hypoxia [1] . HIF-1 is composed of two subunits, an oxygensensitive HIF-1a subunit, and a constitutively expressed HIF-1b subunit. HIF-1 activity is dependent on the availability of the HIF-1a subunit. Under normal oxygen conditions (21% O 2 ), HIF-1a is targeted for ubiquitin-mediated degradation by an E3 ubiquitin ligase complex [2] . This process is dependent on the hydroxylation of two proline residues by a family of prolyl hydroxylase (PHD) enzymes [3] [4] [5] . Under hypoxic conditions, hydroxylation is inhibited and HIF-1a is stabilized [6] . To date the upstream regulators of HIF-1 are poorly understood. The reactive oxygen species (ROS) generated within complex III of mitochondria during hypoxia has been shown by multiple groups to be required and sufficient to activate HIF-1 [6] [7] [8] [9] [10] . However, the direct targets of the mitochondrial ROS or the upstream regulators of HIF-1 remain unresolved. Alternatively, it has been proposed that the mitochondria transduce hypoxic signals by regulating the availability of oxygen for the PHDs to hydroxylate HIF-1a [11, 12] .
AMP-activated kinase (AMPK) is a heterotrimeric serine/ threonine kinase consisting of a catalytic a subunit and two regulatory b and c subunits [13] [14] [15] . AMPK is ubiquitously expressed and functions as an intracellular fuel sensor by maintaining energy balance. Hypoxia, ischemia, and ROS are potent activators of AMPK [16] [17] [18] . Previous work has genetically shown that AMPK is not necessary for HIF-1a protein stability [18] . Yet, other reports have suggested that Compound C prevents HIF-1 activation [19, 20] . To resolve this discrepancy and to investigate whether AMPK is an upstream regulator of HIF-1 we used both Compound C and AMPKa null cells. Here we show that Compound C prevents the hypoxic activation of HIF-1 by suppressing mitochondrial generated ROS independent of AMPK.
Materials and methods

Cell culture and reagents
AmpkaWT, Ampka1
, and Ampka1 À/À 2 À/À mouse embryonic fibroblasts (MEFs), obtained from B. Viollet, were grown in Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/l glucose, L L-glutamine, and sodium pyruvate, supplemented with 10% heat inactivated fetal bovine serum (Gibco), 100 U/ml penicillin, 100 lg/ml streptomycin, 0.25 lg/ml amphotericin B, and 20 mM HEPES. The following reagents were used: Dimethyloxaloylglycine (DMOG) (Frontier Scientific Inc.), Compound C (Calbiochem), and AICA-riboside (AICAR) (Calbiochem).
Oxygen conditions
Hypoxic conditions (1.5% O 2 and 5% CO 2 balanced with N 2 ) were achieved in a humidified variable aerobic workstation (INVIVO O 2 , BioTrace), which contains an oxygen sensor that continuously monitors the chamber oxygen tension.
Immunoblot analysis
HIF-1a protein was analyzed in nuclear extracts as previously described [21] . The anti-HIF-1a antibody (Cayman Chemical) was used and an anti-POL II antibody (Santa Cruz Biotechnology Inc.) as the loading control. For total cell lysates, the following antibodies were used for immunoblotting: AMPKa, acetyl CoA carboxylase (ACC), phospho-acetyl CoA carboxylase (Ser79) (all Cell Signaling Technology Inc.), and an anti-a-tubulin antibody (Sigma-Aldrich Inc.) to control for loading. A representative blot is shown of three independent experiments.
Transfections and reporter assays
Transfections were done using the TransIT Transfection reagent (Mirus) according to manufacturer's protocol. HIF-1 mediated Abbreviations: HIF-1, hypoxia inducible factor 1; AMPK, AMPactivated kinase; DMOG, Dimethyloxaloylglycine; AICAR, AICAriboside; ROS; Reactive oxygen species transcriptional activity was measured using the HRE-Luciferase reporter gene construct, a pGL2 vector containing three hypoxia response elements from the Pgk-1 gene upstream of firefly luciferase. Cells were subjected to conditions for 16 h before lysates were collected. Luciferase values were determined using a dual-luciferase reporter assay kit (Promega). Values for firefly luciferase were normalized to Renilla luciferase under the control of the thymidine kinase promoter in the pRLTK vector. The data presented are the result of triplicate analyses and the error bars indicate standard error of the mean (S.E.M.).
Measurement of cell death
Cell death was measured using a cytotoxicity detection kit (Roche Applied Science) according to manufacturer's protocol. This kit is based on the measurement of lactate dehydrogenase (LDH) that is released into the medium by damaged cells. Cell death is presented as amount of LDH measured in the medium divided by the total LDH released after treatment with 1% Triton X-100. All cell death results are from four independent experiments and are represented as the mean values ± standard error of the mean (S.E.M.).
Measurement of ROS
Intracellular ROS generation was assessed using 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (DCFH-DA) (Molecular Probes). ROS in the cells cause oxidation of DCFH, yielding the fluorescent product 2 0 ,7 0 -dichlorofluorescein (DCF). Cells were plated on Petri dishes and incubated with DCFH-DA (10 lM) under various conditions. The media was then removed, cells were lysed, centrifuged to remove debris, and the fluorescence in the supernatant was measured using a spectrofluorometer (excitation, 500 nm; emission, 530 nm). Data were normalized to values obtained from normoxic, untreated controls.
Oxygen consumption
Cellular O 2 consumption rates were measured in aliquots of 1-2 · 10 6 subconfluent cells removed from flasks and studied in a magnetically stirred, water-jacketed (37°C) anaerobic respirometer fitted with a polarographic O 2 electrode (Oxytherm system; Hansatech Instruments). Oxygraph Plus software was used to determine oxygen consumption rate. The data presented is the result of triplicate analyses and the error bars indicate standard error of the mean (S.E.M.).
Results
Compound C inhibits hypoxic activation of AMPK and
HIF-1 Compound C is known to function as an ATP-competitive inhibitor of AMPK. To first demonstrate that Compound C inhibits the hypoxic activation of AMPK, cells were exposed to 21% O 2 (N), 1.5% O 2 (H), DMOG (D), and AICAR (A) ± Compound C. To assess AMPK activation, lysates were immunoblotted using an antibody that recognizes the phosphorylation site (Ser79) on acetyl-CoA carboxylase (ACC), a direct target of AMPK [14, 22] (Fig. 1A) . As expected, Compound C inhibits both the hypoxic and AICAR induced activation of AMPK, whereas, the hypoxic mimetic DMOG does not activate AMPK (Fig. 1A) . DMOG is a PHD inhibitor which serves as a hypoxic mimetic under normal oxygen conditions, whereas, AICAR mimics AMP, thereby acting as an activator of AMPK. To test the requirement of AMPK for the hypoxic activation of HIF-1, cells were exposed to hypoxia (1.5% O 2 ) or normoxia (21% O 2 ) in the presence or absence of DMOG ± Compound C. Treatment with Compound C completely suppressed the stabilization of the HIF-1a protein under hypoxia, whereas HIF-1a protein level was unaffected with DMOG treatment (Fig. 1B) . These results were further confirmed by examining HIF-1 activity using the HRE-Luciferase assay (Fig. 1C) . Hypoxia and DMOG increased HREdependent luciferase induction in the untreated cells (Fig. 1C) . In contrast, cells treated with Compound C displayed a marked attenuation of luciferase induction under hypoxia but not in the presence of DMOG during normoxia (Fig. 1C) .
AMPK is not required for hypoxic activation of HIF-1
To genetically examine the requirement of AMPK for the hypoxic activation of HIF-1, the double knockout cells for AMPKa1 and AMPKa2, as well as, the individual null cells for AMPKa1 and AMPKa2 were used. First, Ampka WT and the Ampka1 À/À 2 À/À cells were exposed to hypoxia (1.5% O 2 ) or normoxia (21% O 2 ) in the presence or absence of DMOG. Interestingly, the loss of both AMPKa1 and AMPKa2 did not affect HIF-1a protein levels under hypoxia ( Fig. 2A) . Moreover, Ampka1
À/À and Ampka2 À/À cells also displayed no differences in HIF-1a protein levels when subjected to hypoxia (Fig. 2B) . Lastly, the HRE-Luciferase assay displayed no difference between the Ampka WT and the Ampka1 À/À 2 À/À cells under hypoxia (Fig. 2C) , providing genetic evidence that the hypoxic activation of HIF-1 is not dependent on AMPK, coinciding with data published by Laderoute et al. [18] . 
Compound C inhibits hypoxic activation of HIF-1
independent of AMPK To resolve the discrepancy above, a HRE-Luciferase assay was used to examine HIF-1 activity in the Ampka1 À/À 2 À/À in the presence or absence of Compound C. As shown by immunoblotting, these cells are null for AMPKa (Fig. 3A) . Similar to Fig. 2A , hypoxic and DMOG treated Ampka1 À/À 2 À/À cells stabilized the HIF-1a protein (Fig. 3B) . Whereas, treatment with Compound C in the hypoxic Ampka1 À/À 2 À/À cells inhibited HIF-1a protein stability (Fig. 3B) . Furthermore, Compound C had no affect on DMOG treated Ampka1 À/ À 2 À/À cells (Fig. 3B) . Confirming the results shown in Fig. 1C , WT cells treated with Compound C displayed a severe reduction in HRE-Luciferase expression when exposed to hypoxia in comparison to untreated WT cells (Fig. 3C) . Interestingly, hypoxic untreated Ampka1
cells showed an increase in HRE-Luciferase expression, whereas the hypoxic Ampka1 À/À 2 À/À cells treated with Compound C displayed no induction of HRE-Luciferase under hypoxia (Fig. 3C) .
Compound C inhibits mitochondrial function
A functional electron transport chain is required for hypoxic activation of HIF-1. To examine if Compound C prevented HIF-1 activity by inhibiting oxidative phosphorylation, cells adapted to either glucose or galactose were treated with Compound C for 24, 48, and 72 h and cell death was measured by LDH release (Fig. 4A) . Glucose adapted cells treated with Compound C displayed less than 20% cell death at all time points (Fig. 4A) . Untreated galactose adapted cells, which rely entirely on oxidative phosphorylation for survival, showed similar percentages of cell death. Galactose adapted cells display higher oxygen consumption than glucose adapted cells (14.4 nmol/min/million cells vs. 6.34 nmol/min/million cells). Interestingly, galactose adapted cells that were treated with Compound C exhibited near 40% cell death at 48 h and greater than 90% cell death at 72 h (Fig. 4A) . Therefore, Compound C induces cell death in the presence of galactose. To further examine Compound C's effect on respiration, oxygen 
a2
À/À cells transfected with a HRE-Luciferase reporter gene construct and exposed to 21% O 2 ± 1 mM DMOG or to 1.5% O 2 for 16 h before being harvested. Firefly luciferase activity was normalized to renilla luciferase activity and data reported as fold induction over 21% O 2 AMPKa WT. 
À/À cells transfected with a HRE-Luciferase reporter gene construct and exposed to 21% O 2 ± 1 mM DMOG or to 1.5% O 2 ± 20 lM Compound C for 16 h before being harvested. Firefly luciferase activity was normalized to renilla luciferase activity and data reported as fold induction over 21% O 2 AMPKa WT. consumption was measured in WT cells in the presence or absence of Compound C (Figs. 4B and C) . In fact, Compound C inhibits respiration. The likely mechanism is electron transport inhibition since compound C inhibits respiration in the presence of the uncoupler FCCP (10 lM). Previous studies have demonstrated that hypoxia increases the generation of oxidants during the ubiquinione cycle within complex III of the mitochondria and these oxidants are required and sufficient for HIF-1 activation [6] [7] [8] [9] [10] . Indeed, ROS is generated by hypoxia, as detected by the oxidation of the 2 0 ,7 0 -dichlorodihydrofluorescein (DCFH) dye and Compound C suppresses mitochondrial generated oxidants in response to hypoxia (Fig. 4D ). Treatment with DMOG had no effect on ROS generation (Fig. 4D ).
Discussion
Compound C is well established and a potent inhibitor of AMPK. Hypoxia is known to activate AMPK. Consistent with previous reports Compound C prevents hypoxia activation of AMPK. Compound C also inhibits the hypoxic activation of HIF-1, correlating with other reports that have suggested that AMPK is critical for HIF-1 activity by using Compound C under hypoxic conditions or exposure to the carcinogenic metal vanadate [19, 20] . In contrast to the Compound C data, cells deficient in AMPKa1 and a2 are able to still activate HIF-1 during hypoxia. The novel finding in the present study is that Compound C still prevents the hypoxic activation of HIF-1 in cells deficient in both AMPKa1 and a2. This indicates that Compound C can effectively suppress the hypoxic activation of HIF-1 independently of AMPK. Therefore, Compound C can be added to the list of known AMPK modulators, including AICAR and Metformin, which have off target effects. In addition, DN-AMPK adenoviruses have been shown to inhibit the activation of HIF-1, although these approaches also have off target effects [19, 20] . Here we used AMPKa null cells, providing genetics in order to study the requirement of AMPK for the hypoxic activation of HIF-1.
Previous studies have demonstrated that a functional electron transport chain is necessary to produce an increase in ROS that subsequently stabilize HIF-1a in response to hypoxia [6, 7, 9, 10] . Indeed we found that Compound C is also a mitochondrial inhibitor. The actual mitochondrial origin of ROS suppressed by Compound C remains unclear. Bell and colleagues have recently published that the ROS generated by the Q 0 site of complex III is required for hypoxic signaling [6] . Therefore, Compound C may be acting directly or indi- rectly at this site in order to suppress the hypoxic activation of HIF-1. Additionally, Compound C is part of a pyrazolopyrimidine class of protein kinase inhibitors, therefore it is possible that this compound is also inhibiting other kinase signaling pathways that regulate HIF-1 [23] . For example, p38a MAPK is required for the hypoxic activation of HIF-1 [21] . Compound C may influence the p38 MAPK pathway, as well as, inhibit mitochondrial respiration in order to suppress hypoxic signaling. Cells treated with Compound C failed to survive in media containing galactose instead of glucose. Cells adapted to galactose rely on oxidative phosphorylation for survival. Compound C inhibited respiration as measured by oxygen consumption. Furthermore, Compound C suppresses the hypoxia generated increase in ROS, thus providing a mechanistic explanation for why Compound C is effective in suppressing the hypoxic activation of HIF-1. In conclusion, this study demonstrates that Compound C is not only an inhibitor of AMPK, but it inhibits the hypoxic activation of HIF-1 by suppressing mitochondrial generated ROS. These results further highlight the importance of mitochondria as a major regulator of the hypoxic activation of HIF-1.
